Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data
Journal of the American Heart Association · 16.07.2024 · 13 (14)
DOI: 10.1161/jaha.123.033478 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 16.07.2024. Verfasst von Maximilian Leo Müller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology, and Intensive Care Medicine Deutsches Herzzentrum der Charité Berlin Germany. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Results from ATTR‐ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy) indicate that tafamidis prolongs survival and reduces cardiovascular hospitalizations in cardiac transthyretin amyloidosis (ATTR‐CA). However, real‐world data supporting these findings are scarce. Thus, we sought to characterize the clinical outcome of patients with ATTR‐CA treated with tafamidis in a real‐world setting and assess the prognostic role of the New York Heart Association (NYHA) classification. Methods and Results We conducted a retrospective observational study, enrolling a consecutive sample of patients with ATTR‐CA (wild‐type or variant) treated with tafamidis. Clinical outcome was tracked through follow‐up visits or phone calls. Primary outcomes were death and major adverse cardiac events (MACE), a composite end point of death and hospitalizations for acute cardiac decompensation, myocardial infarction, severe arrythmias, or stroke. Kaplan‐Meier analysis estimated overall and MACE‐free survival including NYHA subgroups (NYHA I/II versus NYHA III). One hundred sixty‐seven patients with ATTR‐CA (94.6% wild‐type) were enrolled and followed for a median of 539 [323–869] days. Median overall survival was not reached. Estimated 1‐year, 2‐year, and 5‐year overall survival among the whole cohort was 93.5%, 85.9%, and 70.2%, respectively. Overall survival was higher in the NYHA I/II subgroup ( P =0.002). Median MACE‐free survival time was 1082 (95% CI, 962–1202) days. MACE‐free survival was higher in the NYHA I/II subgroup ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Angiology, and Intensive Care Medicine Deutsches Herzzentrum der Charité Berlin Germany.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin Berlin Germany.
- Berlin Institute of Health (BIH) at Charité Berlin Germany.
- Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
ORCID-Profile: Maximilian Leo Müller, Ekaterina Latinova, Anna Brand, Isabel Mattig, Sebastian Spethmann, Daniel Messroghli, Katrin Hahn, Ulf Landmesser, Bettina Heidecker
Zitieren
APA
Müller, M. L., Latinova, E., Brand, A., Mattig, I., Spethmann, S., Messroghli, D., Hahn, K., Landmesser, U., & Heidecker, B. (2024). Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data. Journal of the American Heart Association, 13(14). https://doi.org/10.1161/jaha.123.033478
Vancouver
Müller ML, Latinova E, Brand A, Mattig I, Spethmann S, Messroghli D, et al. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data. Journal of the American Heart Association. 2024;13(14). doi:10.1161/jaha.123.033478
BibTeX
@article{Mller2024,
author = {Müller, Maximilian Leo and Latinova, Ekaterina and Brand, Anna and Mattig, Isabel and Spethmann, Sebastian and Messroghli, Daniel and Hahn, Katrin and Landmesser, Ulf and Heidecker, Bettina},
title = {Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data},
journal = {Journal of the American Heart Association},
year = {2024},
volume = {13},
number = {14},
doi = {10.1161/jaha.123.033478}
}
EUVIMED